Please login to read the full article.
Scrip Regulatory Affairs
Medtech industry raises concern over US FDA guidance on benefit-risk assessment
21 November 2011
Vibha Sharma
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- US FDA device reviewers to use new worksheet from 1 May to capture benefit-risk determinations
- France votes for more regulatory transparency, tighter safety monitoring and tougher promotion controls
- EU healthcare industries lobby for increased transparency and industry presence in HTA
- AdvaMed seeks more info on US FDA plan to create network of external medtech experts
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
